IDEAYA Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IDYA research report →
Range $39 – $60
Price Chart
About the company
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods.
- CEO
- Yujiro S. Hata
- IPO
- 2019
- Employees
- 145
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on IDYA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.47B
- P/E
- -5.69
- PEG
- 0.04
- P/S
- 67.65
- P/B
- 2.41
- EV/EBITDA
- -5.11
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -1267.38%
- Net Margin
- -1149.62%
- ROE
- -39.52%
- ROIC
- -41.28%
Latest fiscal year · YoY change
- Revenue
- $218.71M+3024.4%
- Gross Profit
- $-95,994,000-3132.0%
- Op Income
- $-159,313,000
- Net Income
- $-113,698,000+58.6%
- EPS
- $-1.28+61.9%
- OCF Growth
- +71.3%
- FCF Growth
- +70.8%
- 52W High
- $42.68
- 52W Low
- $25.46
- 50D MA
- $34.59
- 200D MA
- $33.73
- Beta
- -0.09
- RSI (14)
- 25
- Avg Volume
- 929.62K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
IDEAYA reported encouraging IDE397 Phase 1 data with robust biomarker suppression, a manageable safety profile, and plans to deliver the GSK option package and start expansion/combination studies in mid-2022.· March 15, 2022
- IDE397 showed strong pharmacodynamic activity: plasma SAM reduction across cohorts and exposure-dependent tumor SDMA suppression, including near-complete tumor SDMA knockdown in a cohort 5 lung biopsy.
- Safety so far looked manageable, with low-grade GI events and mild thrombocytopenia, one drug-related Grade 3 asthenia, and no drug-related SAEs or DLTs to date.
- Management said cohort 5 is in the target exposure range for efficacy, and cohort 6 is being enrolled as they consider the expansion dose.
- The GSK option package is planned for mid-2022; if GSK opts in, economics include a $50 million exercise fee, $465 million in development/regulatory milestones, and $475 million in sales milestones.
- The company also said its cash balance was $368 million at year-end 2021, which it said funds operations into 2025.
For full-year 2021, IDEAYA reported operating expenses of $78 million and a cash balance of $368 million, which management said provides runway into 2025. On the IDE397 program, management did not give revenue or EPS figures, but reported dose escalation data showing a mean 77% plasma SAM reduction after three weeks in cohort 5, plasma SAM inhibition of 60% or more across cohorts 1 through 5, and tumor SDMA reduction as high as 95% in a cohort 5 lung biopsy. Management said there were no drug-related serious adverse events or dose-limiting toxicities to date, and the maximum tolerated dose had not yet been reached. Looking ahead, the company targets delivery of the GSK option data package and initiation of monotherapy expansion and combination studies in mid-2022; if GSK opts in, IDEAYA said the arrangement includes a $50 million option fee subject to HSR clearance, an 80/20 cost split in GSK’s favor, $465 million in development/regulatory milestones, $475 million in sales milestones, 50/50 U.S. profit split, and ex-U.S. royalties in the high-single-digit to sub-teens range.
Yujiro Hata framed the quarter as transformational, emphasizing progress across the portfolio and the depth of the IDE397/GSK collaboration. He highlighted that the preclinical package for GSK’s option decision was complete, the FDA protocol amendment had been submitted, and the company is aiming to move into monotherapy expansion and combination testing in mid-2022. His tone was upbeat and confident, while repeatedly stressing that the data support a potential value-accretive partnership structure.
Paul Stone said full-year 2021 operating expenses were $78 million and year-end cash was $368 million, which he said funds operations into 2025. He also reviewed the broader portfolio, noting Darovasertib is advancing in a Phase 2 combo study with crizotinib and a newly expanded Pfizer collaboration for potential registrational work, while IDE161 (PARG) is targeting an IND in Q4 and the GSK-partnered Pol Theta and Werner programs are also progressing. His comments were largely about balance-sheet strength, runway, and multiple upcoming catalysts rather than quarter-to-quarter P&L trends.
Analysts focused heavily on the GSK opt-in process, asking when the data room would be complete, whether cohort 6 data would be included, and whether GSK needs an MTD before deciding. Management said the package is based on the expansion dose selected or MTD, not necessarily MTD itself, and that they expect the package delivery and opt-in decision could be in close proximity. Questions also probed SDMA biomarker interpretation, baseline H-scores, liver safety versus prior agents, and whether combination or response/progression data would factor into GSK’s decision; management said the option package is limited to the defined PK/PD and safety categories, response data is not required, and the clinical tumor data set is still too small to define thresholds or variability. On safety, management said the one Grade 3 event occurred at dose level 4 and there has been no significant liver toxicity seen so far.
The call presented IDE397 as having both biological activity and a clean-enough safety profile to keep dosing and expansion moving. Management believes cohort 6 is already in the efficacy range, tumor SDMA suppression is strong and exposure-dependent, and the drug may support both monotherapy and combinations with less dose-limiting toxicity than earlier MAT2A/PRMT5 drugs.
The clinical dataset is still early, especially for paired tumor biopsies, so management repeatedly said it is too soon to define exact efficacy thresholds or predict which patients will benefit. There are also open questions around how much further dose escalation is needed, whether cohort 6 will be the expansion dose, and when exactly GSK will make its opt-in decision. Additionally, management acknowledged that prior pathway drugs have struggled with toxicity, and the company is still in the process of proving that the biomarker effects translate into clinical responses.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 93.4%
- Shares Outstanding
- 96.69M
- Float Shares
- 90.27M
of shares held by institutions
294 13F filers
Buy/sell ratio 0.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 14.47M | ▲ 363.10K |
| Blackrock, Inc. | 9.55M | ▲ 655.27K |
| Janus Henderson Group Ltd. | 8.62M | ▲ 8.62M |
| Jupiter Topco LLC | 8.58M | ▲ 8.58M |
| Capital Research Global Investors | 5.34M | ▼ 3.76K |
| Vanguard Group Inc | 5.02M | ▲ 97.12K |
| Baker Bros. Advisors LP | 5.01M | 0 |
| Vanguard Capital Management LLC | 4.31M | ▲ 179.06K |
| State Street Corp | 3.93M | ▼ 621.20K |
| Logos Global Management LP | 2.85M | ▼ 150.00K |
| Adage Capital Partners Gp, L.L.C. | 2.72M | 0 |
| Geode Capital Management, LLC | 2.54M | ▲ 119.11K |
Held by 334 ETFs
Biggest fund positions in IDYA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 6, 26 | Hata Yujiro S | other | 26,338 |
| Oct 6, 26 | Hata Yujiro S | sell | 25,538 |
| Oct 6, 26 | Hata Yujiro S | sell | 800 |
| Oct 6, 26 | Hata Yujiro S | other | 26,338 |
| Jul 7, 26 | Ruiz Briseno Andres | other | 9,550 |
| Jul 7, 26 | Ruiz Briseno Andres | sell | 9,550 |
| Jul 7, 26 | Ruiz Briseno Andres | other | 9,550 |
| Jun 16, 26 | YARNO WENDY L | other | 20,000 |
| Jun 16, 26 | Stein Jeffrey | other | 20,000 |
| Jun 16, 26 | ROSEN TERRY J | other | 20,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IDYA coverage
Recent articles, reports, and earnings notes.
No research on IDYA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IDYA report →IDEAYA Biosciences, Inc. (IDYA) Discusses Pipeline Updates Across MTAP Deletion, PRMT5 and KAT67 Programs Transcript
seekingalpha.com · Nov 20
IDEAYA Biosciences, Inc. $IDYA Shares Bought by Aberdeen Group plc
defenseworld.net · Nov 18
Ideaya Biosciences: Staying Bullish On Darovasertib NDA Submission And More
seekingalpha.com · Nov 17
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas
prnewswire.com · Nov 16
IDEAYA Biosciences, Inc. (IDYA) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 16
IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors
gurufocus.com · Nov 15
IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors
prnewswire.com · Nov 15
IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
prnewswire.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.